Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions

L. I. Sun, Weiping Li, Weizu Li, L. I. Xiong, Guiping Li, Rong Ma

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

Glomerular hypertrophy and hyperfiltration are the two major pathological characteristics of the early stages of diabetic nephropathy (DN), which are respectively related to mesangial cell (MC) proliferation and a decrease in calcium influx conducted by canonical transient receptor potential cation channel 6 (TRPC6). The marked increase in the production of reactive oxygen species (ROS) induced by hyperglycemia is the main sponsor of multiple pathological pathways in DN. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an important source of ROS production in MCs. Astragaloside IV (AS-IV) is an active ingredient of Radix Astragali which has a potent antioxidative effect. In this study, we aimed to investigate whether high glucose (HG)-induced NADPH oxidase activation and ROS production contribute to MC proliferation and the downregulation of TRPC6 expression; we also wished to determine the effects of AS-IV on MCs under HG conditions. Using a human glomerular mesangial cell line, we found that treatment with AS-IV for 48 h markedly attenuated HG-induced proliferation and the hypertrophy of MCs in a dose-dependent manner. The intracellular ROS level was also markedly reduced following treatment with AS-IV. In addition, the enhanced activity of NADPH oxidase and the expression level of NADPH oxidase 4 (Nox4) protein were decreased. Treatment with AS-IV also inhibited the phosphorylation level of Akt and IκBα in the MCs. In addition, TRPC6 protein expression and the intracellular free calcium concentration were also markedly reduced following treatment with AS-IV under HG conditions. These results suggest that AS-IV inhibits HG-induced mesangial cell proliferation and glomerular contractile dysfunction through the NADPH oxidase/ROS/Akt/nuclear factor-κB (NF-κB) pathway, providing a new perspective for the clinical treatment of DN.

Original languageEnglish
Pages (from-to)167-176
Number of pages10
JournalInternational journal of molecular medicine
Volume34
Issue number1
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Mesangial Cells
NADP
Reactive Oxygen Species
Oxidoreductases
Glucose
Transient Receptor Potential Channels
Diabetic Nephropathies
Cell Proliferation
Hypertrophy
Calcium
astragaloside A
Hyperglycemia
Proteins
Down-Regulation
Phosphorylation
Cell Line

Keywords

  • Astragaloside IV
  • Diabetic nephropathy
  • Human mesangial cells
  • Nicotinamide adenine dinucleotide phosphate oxidase
  • Reactive oxygen species

Cite this

@article{9aeb2cb1c28e4ca98af0e6edba44f8c3,
title = "Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions",
abstract = "Glomerular hypertrophy and hyperfiltration are the two major pathological characteristics of the early stages of diabetic nephropathy (DN), which are respectively related to mesangial cell (MC) proliferation and a decrease in calcium influx conducted by canonical transient receptor potential cation channel 6 (TRPC6). The marked increase in the production of reactive oxygen species (ROS) induced by hyperglycemia is the main sponsor of multiple pathological pathways in DN. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an important source of ROS production in MCs. Astragaloside IV (AS-IV) is an active ingredient of Radix Astragali which has a potent antioxidative effect. In this study, we aimed to investigate whether high glucose (HG)-induced NADPH oxidase activation and ROS production contribute to MC proliferation and the downregulation of TRPC6 expression; we also wished to determine the effects of AS-IV on MCs under HG conditions. Using a human glomerular mesangial cell line, we found that treatment with AS-IV for 48 h markedly attenuated HG-induced proliferation and the hypertrophy of MCs in a dose-dependent manner. The intracellular ROS level was also markedly reduced following treatment with AS-IV. In addition, the enhanced activity of NADPH oxidase and the expression level of NADPH oxidase 4 (Nox4) protein were decreased. Treatment with AS-IV also inhibited the phosphorylation level of Akt and IκBα in the MCs. In addition, TRPC6 protein expression and the intracellular free calcium concentration were also markedly reduced following treatment with AS-IV under HG conditions. These results suggest that AS-IV inhibits HG-induced mesangial cell proliferation and glomerular contractile dysfunction through the NADPH oxidase/ROS/Akt/nuclear factor-κB (NF-κB) pathway, providing a new perspective for the clinical treatment of DN.",
keywords = "Astragaloside IV, Diabetic nephropathy, Human mesangial cells, Nicotinamide adenine dinucleotide phosphate oxidase, Reactive oxygen species",
author = "Sun, {L. I.} and Weiping Li and Weizu Li and Xiong, {L. I.} and Guiping Li and Rong Ma",
year = "2014",
month = "1",
day = "1",
doi = "10.3892/ijmm.2014.1741",
language = "English",
volume = "34",
pages = "167--176",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "1",

}

Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions. / Sun, L. I.; Li, Weiping; Li, Weizu; Xiong, L. I.; Li, Guiping; Ma, Rong.

In: International journal of molecular medicine, Vol. 34, No. 1, 01.01.2014, p. 167-176.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions

AU - Sun, L. I.

AU - Li, Weiping

AU - Li, Weizu

AU - Xiong, L. I.

AU - Li, Guiping

AU - Ma, Rong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Glomerular hypertrophy and hyperfiltration are the two major pathological characteristics of the early stages of diabetic nephropathy (DN), which are respectively related to mesangial cell (MC) proliferation and a decrease in calcium influx conducted by canonical transient receptor potential cation channel 6 (TRPC6). The marked increase in the production of reactive oxygen species (ROS) induced by hyperglycemia is the main sponsor of multiple pathological pathways in DN. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an important source of ROS production in MCs. Astragaloside IV (AS-IV) is an active ingredient of Radix Astragali which has a potent antioxidative effect. In this study, we aimed to investigate whether high glucose (HG)-induced NADPH oxidase activation and ROS production contribute to MC proliferation and the downregulation of TRPC6 expression; we also wished to determine the effects of AS-IV on MCs under HG conditions. Using a human glomerular mesangial cell line, we found that treatment with AS-IV for 48 h markedly attenuated HG-induced proliferation and the hypertrophy of MCs in a dose-dependent manner. The intracellular ROS level was also markedly reduced following treatment with AS-IV. In addition, the enhanced activity of NADPH oxidase and the expression level of NADPH oxidase 4 (Nox4) protein were decreased. Treatment with AS-IV also inhibited the phosphorylation level of Akt and IκBα in the MCs. In addition, TRPC6 protein expression and the intracellular free calcium concentration were also markedly reduced following treatment with AS-IV under HG conditions. These results suggest that AS-IV inhibits HG-induced mesangial cell proliferation and glomerular contractile dysfunction through the NADPH oxidase/ROS/Akt/nuclear factor-κB (NF-κB) pathway, providing a new perspective for the clinical treatment of DN.

AB - Glomerular hypertrophy and hyperfiltration are the two major pathological characteristics of the early stages of diabetic nephropathy (DN), which are respectively related to mesangial cell (MC) proliferation and a decrease in calcium influx conducted by canonical transient receptor potential cation channel 6 (TRPC6). The marked increase in the production of reactive oxygen species (ROS) induced by hyperglycemia is the main sponsor of multiple pathological pathways in DN. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is an important source of ROS production in MCs. Astragaloside IV (AS-IV) is an active ingredient of Radix Astragali which has a potent antioxidative effect. In this study, we aimed to investigate whether high glucose (HG)-induced NADPH oxidase activation and ROS production contribute to MC proliferation and the downregulation of TRPC6 expression; we also wished to determine the effects of AS-IV on MCs under HG conditions. Using a human glomerular mesangial cell line, we found that treatment with AS-IV for 48 h markedly attenuated HG-induced proliferation and the hypertrophy of MCs in a dose-dependent manner. The intracellular ROS level was also markedly reduced following treatment with AS-IV. In addition, the enhanced activity of NADPH oxidase and the expression level of NADPH oxidase 4 (Nox4) protein were decreased. Treatment with AS-IV also inhibited the phosphorylation level of Akt and IκBα in the MCs. In addition, TRPC6 protein expression and the intracellular free calcium concentration were also markedly reduced following treatment with AS-IV under HG conditions. These results suggest that AS-IV inhibits HG-induced mesangial cell proliferation and glomerular contractile dysfunction through the NADPH oxidase/ROS/Akt/nuclear factor-κB (NF-κB) pathway, providing a new perspective for the clinical treatment of DN.

KW - Astragaloside IV

KW - Diabetic nephropathy

KW - Human mesangial cells

KW - Nicotinamide adenine dinucleotide phosphate oxidase

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=84902653456&partnerID=8YFLogxK

U2 - 10.3892/ijmm.2014.1741

DO - 10.3892/ijmm.2014.1741

M3 - Article

VL - 34

SP - 167

EP - 176

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 1

ER -